Amarin Corporation Submits sNDA for Vascepa

Share this article:

Amarin Corporation announced that it has submitted a Supplemental New Drug Application (sNDA) to the FDA seeking approval for the marketing and sale of Vascepa (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG = 200–500mg/dL) with mixed dyslipidemia. Vascepa is a pure-EPA omega-3 prescription medication supplied in a 1 gram capsule.

Vascepa is currently indicated as an adjunct to diet to reduce TG levels in adult patients with severe (TG ≥500mg/dL) hypertriglyceridemia.

For more information call (908) 719-1315 or visit www.amarincorp.com
Share this article:

Related Resources